1. Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs).
- Author
-
Shi, Zheng, Zeng, Xiaohong, Sun, Wei, Xu, Manyi, Shao, Keda, Wei, Jingwen, Xu, Chunwei, and Song, Zhengbo
- Subjects
PLATINUM compounds ,PATIENT safety ,RESEARCH funding ,ANTINEOPLASTIC agents ,SALIVARY gland tumors ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,CANCER chemotherapy ,KAPLAN-Meier estimator ,LOG-rank test ,LUNG tumors ,DRUG efficacy ,MEDICAL records ,ACQUISITION of data ,LUNG cancer ,SURVIVAL analysis (Biometry) ,PACLITAXEL - Abstract
Primary pulmonary salivary gland tumors (PSGT) constitute a rare subtype of non-small cell lung cancer (NSCLC). Currently, no established treatment guidelines exist for advanced PSGT. The efficacy of platinum-based chemotherapy for PSGT within the context of NSCLC remains uncertain. Therefore, we retrospectively collected 37 PSGT patients who underwent first-line platinum-based chemotherapy from 2010 to 2023. Survival analysis, employing the Kaplan–Meier method, and group comparisons via the log rank test were conducted. Our results show that first-line platinum-based chemotherapy demonstrates favorable efficacy and manageable safety in advanced PSGT, with the combination of Paclitaxel + Platinum emerging as a preferred option. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF